Who
Andrew J. Fromkin
Director
Company insider
Files Form 4 as: Director, Immunovant; Director, Tobira Therapeutics; President & CEO, Radius Health; CEO, President, Clinical Data.
In numbers
- Trades disclosed
- 96
- Buys
- 7
- Sells
- 4
- Bought
- $197K
- Sold
- $16.0M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 12 May 2006
- Last trade
- 28 May 2026
- Last filed
- 29 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 May 2026filed 29 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $158K31,668 at $4.99 | filing |
| 28 May 2026filed 29 May 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,260 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $568K71,492 at $7.94 | filing |
| 28 May 2026filed 29 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $651K77,181 at $8.43 | filing |
| 28 May 2026filed 29 May 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code M | —31,668 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code M | —71,492 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code M | —77,181 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,260 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $239K16,260 at $14.70 | filing |
| 28 May 2026filed 29 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $375K11,483 at $32.64 | filing |
| 28 May 2026filed 29 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $7.1M210,468 at $33.56 | filing |
| 28 May 2026filed 29 May 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code M | —31,668 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code M | —71,492 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $158K31,668 at $4.99 | filing |
| 28 May 2026filed 29 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $568K71,492 at $7.94 | filing |
| 28 May 2026filed 29 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $651K77,181 at $8.43 | filing |
| 28 May 2026filed 29 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $239K16,260 at $14.70 | filing |
| 28 May 2026filed 29 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $375K11,483 at $32.64 | filing |
| 28 May 2026filed 29 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $7.1M210,468 at $33.56 | filing |
| 28 May 2026filed 29 May 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code M | —77,181 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.